Tag: FDA

Complex Generic Formulations: Why Proving Bioequivalence Is So Hard

Proving bioequivalence for complex generics like inhalers, topical creams, and liposomal injections is far harder than for regular pills. Without reliable tests, unclear regulations, and reverse-engineering hurdles, only 10-15% of these products get approved-despite a $120 billion market gap.